MedXY – Page 15

Impact of Maternal Pertussis Vaccination on Infant Immune Responses: Insights from the GaPS Trial in The Gambia

By MedXY 08/02/2025

A phase 4 trial in The Gambia finds that maternal Tdap-IPV vaccination is safe and provides early infant protection, but modestly blunts immune responses to whole-cell pertussis vaccines without compromising overall immunogenicity.

Clinical Updates Wellness & Lifestyle

Individualised Versus Standard 10-Day Antibiotic Therapy in Pediatric Febrile UTI: Insights from the INDI-UTI Trial

By MedXY 08/02/2025

A Danish multicentre trial found individualised, shorter antibiotic regimens for febrile pediatric UTIs reduce overall antibiotic exposure and adverse events, but with a modestly higher recurrence risk compared to standard 10-day treatment.

Clinical Updates Wellness & Lifestyle

Doxycycline Post-Exposure Prophylaxis Significantly Reduces Bacterial STIs Among MSM and Transgender Women: Final Results from the DoxyPEP Trial

By MedXY 08/02/2025

The DoxyPEP trial demonstrates that doxycycline post-exposure prophylaxis markedly lowers bacterial STI incidence in men who have sex with men and transgender women, with good tolerability and minimal resistance over 12 months.

Clinical Updates

Efficacy and Safety of High-Dose Versus Low-Dose Primaquine for Plasmodium vivax in Cambodia: A Randomised Controlled Trial

By MedXY 08/02/2025

A Cambodian study shows that a 14-day high-dose primaquine regimen (7.0 mg/kg) significantly reduces Plasmodium vivax relapse compared to the standard low-dose (3.5 mg/kg), with comparable safety in G6PD-normal patients.

Clinical Updates Medical News

Guselkumab for Crohn’s Disease and Ulcerative Colitis: Efficacy and Safety from Recent Phase 3 Trials

By MedXY 08/02/2025

Phase 3 studies demonstrate guselkumab's efficacy and safety as induction and maintenance therapy for moderate-to-severe Crohn's disease and ulcerative colitis, with superiority over placebo and favorable safety profiles.

Clinical Updates

Prademagene Zamikeracel: A Breakthrough Gene Therapy for Chronic Wounds in Recessive Dystrophic Epidermolysis Bullosa (RDEB)

By MedXY 08/02/2025

A phase 3 trial demonstrates prademagene zamikeracel significantly accelerates healing and reduces pain in large, chronic RDEB wounds, offering a promising gene therapy with a favorable safety profile.

Clinical Updates Wellness & Lifestyle

Amycretin: A Novel Unimolecular GLP-1 and Amylin Receptor Agonist for Obesity – Early-Phase Clinical Insights and Broader GLP-1 Drug Development Perspective

By MedXY 08/02/2025

Amycretin, a new unimolecular GLP-1 and amylin agonist, demonstrated significant weight loss and acceptable tolerability in a phase 1b/2a study, underscoring its potential as an anti-obesity therapy.

Clinical Updates

Type 2 Inflammation Biomarkers and Dupilumab Response in COPD: Insights from the BOREAS Phase 3 Trial

By MedXY 08/02/2025

Dupilumab significantly reduced type 2 inflammation biomarkers and exacerbation risk in COPD patients with elevated eosinophils, highlighting the value of biomarker-driven therapy.

Clinical Updates Wellness & Lifestyle

Short-Course Radiotherapy Plus Sintilimab and Chemotherapy as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the SPRING-01 Trial

By MedXY 08/02/2025

Adding sintilimab to short-course radiotherapy and chemotherapy significantly increased pathological complete response rates in locally advanced rectal cancer, with manageable safety.

Clinical Updates Wellness & Lifestyle

Metformin in Prostate Cancer: Revisiting Hopes and Realities After Recent Phase 3 Trials

By MedXY 08/02/2025

Recent large RCTs show metformin does not improve survival or reduce metabolic syndrome risk in prostate cancer patients on ADT, though it modestly improves metabolic parameters.